Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer
Latest Information Update: 02 Sep 2020
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-08
- 31 Aug 2020 Results published in the British Journal of Cancer
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.